Drug Monograph

Drug Name: **Casirivimab/Imdevimab vial**
Drug Class: **COVID-19 Monoclonal Antibodies**
Prepared For: MO HealthNet
Prepared By: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Casirivimab/Imdevimab is available in a 300 mg/300 mg and a 1332 mg/1332 mg two-pack of vials.
Manufacturer:	Manufactured by: Regeneron Pharmaceuticals, Inc. Tarrytown, NY 10591.
Indications:	The U.S. food and Drug Administration (FDA) has issues an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, REGEN-COV (casirivimab and imdevimab) co-formulated product and REGEN-COV (casirivimab and imdevimab) supplied as individual vials to be administered together, for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adult and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Costs:	$0.00 (from National Stockpile)
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	☐ Clinical Edit ☐ PA Required ☒ Open Access ☐ PDL
Type of PA Criteria:	☐ Appropriate Indications ☐ Non-Preferred ☒ No PA Required ☐ Preferred

Prepared by: April Ash, PharmD
Date: December 30, 2021